Cargando…

LEP as a potential biomarker in prognosis of breast cancer: Systemic review and meta analyses (PRISMA)

PURPOSE: Obesity strongly affects the prognosis of various malignancies, including breast cancer. Leptin (LEP) may be associated with obesity and breast cancer prognosis. The purpose of our study was to determine the prognostic value of LEP in breast cancer. METHOD: We conducted a multi-omic analysi...

Descripción completa

Detalles Bibliográficos
Autores principales: Jin, Tong Yi, Saindane, Madhuri, Park, Kyoung Sik, Kim, SeongHoon, Nam, SangEun, Yoo, YoungBum, Yang, Jung-Hyun, Yun, IkJin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8376305/
https://www.ncbi.nlm.nih.gov/pubmed/34414945
http://dx.doi.org/10.1097/MD.0000000000026896
_version_ 1783740466551848960
author Jin, Tong Yi
Saindane, Madhuri
Park, Kyoung Sik
Kim, SeongHoon
Nam, SangEun
Yoo, YoungBum
Yang, Jung-Hyun
Yun, IkJin
author_facet Jin, Tong Yi
Saindane, Madhuri
Park, Kyoung Sik
Kim, SeongHoon
Nam, SangEun
Yoo, YoungBum
Yang, Jung-Hyun
Yun, IkJin
author_sort Jin, Tong Yi
collection PubMed
description PURPOSE: Obesity strongly affects the prognosis of various malignancies, including breast cancer. Leptin (LEP) may be associated with obesity and breast cancer prognosis. The purpose of our study was to determine the prognostic value of LEP in breast cancer. METHOD: We conducted a multi-omic analysis to determine the prognostic role of LEP. Different public bioinformatics platforms (Oncomine, Gene Expression Profiling Interactive Analysis, University of California Santa Cruz Xena, bc-GenExMiner, PrognoScan database, R2-Kaplan–Meier Scanner, UALCAN, Search Tool for the Retrieval of Interacting Genes/Proteins database , and The Database for Annotation, Visualization and Integrated Discovery) were used to evaluate the roles of LEP. Clinicopathological variables were evaluated. RESULTS: LEP was downregulated in breast cancer tissues compared to levels in normal tissues. By co-expressed gene analysis, a positive correlation between LEP and SLC19A3 was observed. Based on the clinicopathological analysis, low LEP expression was associated with older age, higher stage, lymph node status, human epidermal growth factor receptor 2 (HER2) status, estrogen receptor (ER+) positivity, and progesterone receptor (PR+) positivity. Kaplan–Meier survival analysis showed that low LEP expression indicated a poorer prognosis. LEP is hypermethylated in breast cancer tissues in PrognoScan and R2-Kaplan Meier Scanner, and low LEP expression was correlated with poor prognosis. LEP protein–protein interactions were analyzed using Search Tool for the Retrieval of Interacting Genes/Proteins database. Gene ontology analysis results showed that cellular component is mainly associated with the endosome lumen, cytosol, and secretory granules and is upregulated. For the biological process energy reserve, metabolic processes exhibited the greatest regulation compared to the others. In molecular function, it was mainly enriched in a variety of combinations, but hormone activity showed the highest regulation. CONCLUSION: Our study provides evidence for the prognostic role of LEP in breast cancer and as a novel potential therapeutic target in such malignancies. Nevertheless, further validation is required.
format Online
Article
Text
id pubmed-8376305
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-83763052021-08-21 LEP as a potential biomarker in prognosis of breast cancer: Systemic review and meta analyses (PRISMA) Jin, Tong Yi Saindane, Madhuri Park, Kyoung Sik Kim, SeongHoon Nam, SangEun Yoo, YoungBum Yang, Jung-Hyun Yun, IkJin Medicine (Baltimore) 5750 PURPOSE: Obesity strongly affects the prognosis of various malignancies, including breast cancer. Leptin (LEP) may be associated with obesity and breast cancer prognosis. The purpose of our study was to determine the prognostic value of LEP in breast cancer. METHOD: We conducted a multi-omic analysis to determine the prognostic role of LEP. Different public bioinformatics platforms (Oncomine, Gene Expression Profiling Interactive Analysis, University of California Santa Cruz Xena, bc-GenExMiner, PrognoScan database, R2-Kaplan–Meier Scanner, UALCAN, Search Tool for the Retrieval of Interacting Genes/Proteins database , and The Database for Annotation, Visualization and Integrated Discovery) were used to evaluate the roles of LEP. Clinicopathological variables were evaluated. RESULTS: LEP was downregulated in breast cancer tissues compared to levels in normal tissues. By co-expressed gene analysis, a positive correlation between LEP and SLC19A3 was observed. Based on the clinicopathological analysis, low LEP expression was associated with older age, higher stage, lymph node status, human epidermal growth factor receptor 2 (HER2) status, estrogen receptor (ER+) positivity, and progesterone receptor (PR+) positivity. Kaplan–Meier survival analysis showed that low LEP expression indicated a poorer prognosis. LEP is hypermethylated in breast cancer tissues in PrognoScan and R2-Kaplan Meier Scanner, and low LEP expression was correlated with poor prognosis. LEP protein–protein interactions were analyzed using Search Tool for the Retrieval of Interacting Genes/Proteins database. Gene ontology analysis results showed that cellular component is mainly associated with the endosome lumen, cytosol, and secretory granules and is upregulated. For the biological process energy reserve, metabolic processes exhibited the greatest regulation compared to the others. In molecular function, it was mainly enriched in a variety of combinations, but hormone activity showed the highest regulation. CONCLUSION: Our study provides evidence for the prognostic role of LEP in breast cancer and as a novel potential therapeutic target in such malignancies. Nevertheless, further validation is required. Lippincott Williams & Wilkins 2021-08-20 /pmc/articles/PMC8376305/ /pubmed/34414945 http://dx.doi.org/10.1097/MD.0000000000026896 Text en Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0 (https://creativecommons.org/licenses/by/4.0/)
spellingShingle 5750
Jin, Tong Yi
Saindane, Madhuri
Park, Kyoung Sik
Kim, SeongHoon
Nam, SangEun
Yoo, YoungBum
Yang, Jung-Hyun
Yun, IkJin
LEP as a potential biomarker in prognosis of breast cancer: Systemic review and meta analyses (PRISMA)
title LEP as a potential biomarker in prognosis of breast cancer: Systemic review and meta analyses (PRISMA)
title_full LEP as a potential biomarker in prognosis of breast cancer: Systemic review and meta analyses (PRISMA)
title_fullStr LEP as a potential biomarker in prognosis of breast cancer: Systemic review and meta analyses (PRISMA)
title_full_unstemmed LEP as a potential biomarker in prognosis of breast cancer: Systemic review and meta analyses (PRISMA)
title_short LEP as a potential biomarker in prognosis of breast cancer: Systemic review and meta analyses (PRISMA)
title_sort lep as a potential biomarker in prognosis of breast cancer: systemic review and meta analyses (prisma)
topic 5750
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8376305/
https://www.ncbi.nlm.nih.gov/pubmed/34414945
http://dx.doi.org/10.1097/MD.0000000000026896
work_keys_str_mv AT jintongyi lepasapotentialbiomarkerinprognosisofbreastcancersystemicreviewandmetaanalysesprisma
AT saindanemadhuri lepasapotentialbiomarkerinprognosisofbreastcancersystemicreviewandmetaanalysesprisma
AT parkkyoungsik lepasapotentialbiomarkerinprognosisofbreastcancersystemicreviewandmetaanalysesprisma
AT kimseonghoon lepasapotentialbiomarkerinprognosisofbreastcancersystemicreviewandmetaanalysesprisma
AT namsangeun lepasapotentialbiomarkerinprognosisofbreastcancersystemicreviewandmetaanalysesprisma
AT yooyoungbum lepasapotentialbiomarkerinprognosisofbreastcancersystemicreviewandmetaanalysesprisma
AT yangjunghyun lepasapotentialbiomarkerinprognosisofbreastcancersystemicreviewandmetaanalysesprisma
AT yunikjin lepasapotentialbiomarkerinprognosisofbreastcancersystemicreviewandmetaanalysesprisma